Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Enoxaparin sodium 100 mg/mL Injection, ampoule and pre-filled syringe Rhone-Poulenc Rorer Pharma Specialites, Maisons-Alfort, France Clexane Ganciclovir 250 mg Capsule, powder filled Syntex Puerto Rico Inc., Humacao, Puerto Rico and Roche Products Limited, Welwyn Garden City, Hertfordshire, United Kingdom Cymevene Benzydarmine hydrochloride 10 mg/g, cetylpyridinium chloride 1 mg/g Gel, oral 3M Pharmaceuticals (Australia) Pty Limited, Thornleigh, New South Wales, Australia Difflam Anti-inflammatory Anti-septic Mouth Gel Fluticasone propionate 25 g/dose, 50 g/dose Inhaler, aerosol, metered Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia; Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom; Glaxo Wellcome Production, Evreux, France and Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom Flixotide Cladribine 1 mg/mL Infusion, solution Janssen Pharmaceutica Inc., Fort Washington, Pennsylvania, United States of America and OMJ Pharmaceuticals Inc., San German, Puerto Rico Leustatin Itraconazole 10 mg/mL Solution, oral Janssen Pharmaceutica nv., Beerse, Belgium Sporanox Fexofenadine hydrochloride 120 mg, 180 mg Tablets Hoechst Marion Roussel Inc., Kansas City, Missouri, United States of America Telfast Lisinopril dihydrate 5.45 mg, 10.89 mg, 21.78 mg, equivalent to 5 mg, 10 mg, 20 mg lisinopril Tablets Zeneca Pharma, La Pompelle, Reims, France and Zeneca Pharmaceuticals, Macclesfield, Cheshire, England Zestril Goserelin acetate 3.6 mg Implant, subcutaneous Zeneca Pharmaceuticals, Macclesfield, Cheshire, England Zoladex Injectable Implant Dated this 19th day of May 1998. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.